These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25615583)

  • 21. Is hepatitis C virus eradication around the corner only 25 years after its discovery?
    Ippolito G; Capobianchi MR; Lanini S; Antonelli G
    Int J Antimicrob Agents; 2015 Feb; 45(2):111-2. PubMed ID: 25249016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Access to hepatitis C medicines.
    Edwards DJ; Coppens DG; Prasad TL; Rook LA; Iyer JK
    Bull World Health Organ; 2015 Nov; 93(11):799-805. PubMed ID: 26549908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings.
    Easterbrook P; Sands A; Harmanci H
    Semin Liver Dis; 2012 May; 32(2):147-57. PubMed ID: 22760654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment.
    Walsh N; Maher L
    Curr Opin HIV AIDS; 2012 Jul; 7(4):339-44. PubMed ID: 22498482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers.
    Bruggmann P
    J Viral Hepat; 2012 Dec; 19(12):829-35. PubMed ID: 23205675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030.
    Sonderup MW; Afihene M; Ally R; Apica B; Awuku Y; Cunha L; Dusheiko G; Gogela N; Lohouès-Kouacou MJ; Lam P; Lesi O; Mbaye PS; Musabeyezu E; Musau B; Ojo O; Rwegasha J; Scholz B; Shewaye AB; Tzeuton C; Kassianides C; Spearman CW;
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):910-919. PubMed ID: 29132760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Need of righteous attitudes towards eradication of hepatitis C virus infection in Latin America.
    Panduro A; Roman S
    World J Gastroenterol; 2016 Jun; 22(22):5137-42. PubMed ID: 27298556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A public health approach to hepatitis C control in low- and middle-income countries.
    Suthar AB; Harries AD
    PLoS Med; 2015 Mar; 12(3):e1001795. PubMed ID: 25757228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2015 Mar; 22(3):213-29. PubMed ID: 25270261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human rights and access to hepatitis C treatment for people who inject drugs.
    Wolfe D; Luhmann N; Harris M; Momenghalibaf A; Albers E; Byrne J; Swan T
    Int J Drug Policy; 2015 Nov; 26(11):1072-80. PubMed ID: 26232055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations for the management of hepatitis C virus infection among people who inject drugs.
    Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S129-37. PubMed ID: 23884061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
    Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
    Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to improve access to therapy in hepatitis B patients.
    Subic M; Zoulim F
    Liver Int; 2018 Feb; 38 Suppl 1():115-121. PubMed ID: 29427482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment as prevention and cure towards global eradication of hepatitis C virus.
    Hagan LM; Wolpe PR; Schinazi RF
    Trends Microbiol; 2013 Dec; 21(12):625-33. PubMed ID: 24238778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C: a changing epidemic.
    Wandeler G; Dufour JF; Bruggmann P; Rauch A
    Swiss Med Wkly; 2015; 145():w14093. PubMed ID: 25658972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV/hepatitis C virus coinfection management: changing guidelines and changing paradigms.
    Cooper CL; Klein MB
    HIV Med; 2014 Nov; 15(10):621-4. PubMed ID: 24802099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Access to HCV treatments: hurdles not barriers.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):1. PubMed ID: 28404005
    [No Abstract]   [Full Text] [Related]  

  • 38. A Modifiable Barrier to Hepatitis C Virus Elimination in Rhode Island: The Prior Authorization Process for Direct-Acting Antiviral Agents.
    Duryea P; Habchi J; Sprecht-Walsh S; Thomas AM; Bratberg J
    R I Med J (2013); 2020 Jun; 103(5):41-44. PubMed ID: 32481779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic.
    Bajis S; Applegate TL; Grebely J; Matthews GV; Dore GJ
    J Infect Dis; 2020 Nov; 222(Suppl 9):S758-S772. PubMed ID: 33245354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C: Is eradication possible?
    Lombardi A; Mondelli MU;
    Liver Int; 2019 Mar; 39(3):416-426. PubMed ID: 30472772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.